Type 2 diabetes MedDRA version: 9.1 Level: LLT Classification code 10029505 Term: Non-insulin-dependent diabetes mellitus
Conditions
Sponsors
AstraZeneca AB
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Provision of informed consent 2. Diagnosed with type 2 diabetes 3. Men or women above or equal to 18 years 4. Women of childbearing potential must be using an adequate method of contraception 5. Treatment with metformin alone on a stable dose of 1500 mg or higher per day for at least 8 weeks prior to visit 1 6. HbA1c higher than 6.5% and less than or equal to 10.0% at lead in visit Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Type 1 diabetes, history of diabetic ketoacidosis or hyperosmolar non-ketonic coma 2. Pregnant or breastfeeding patients 3. Insulin therapy within 1 year of enrolment 4. Previous treatment with any DPP-4 inhibitor 5. Treatment with thiazolidindione within 12 weeks prior to visit 1 6. Treatment with systemic glucocorticoids other than replacement therapy 7. Treatment with Cytochrome P450 3A4 inducers 8. Treatment with human immunodeficiency virus (HIV) treatment 9. Potential allergy to metformin, saxagliptin, glipizide, or placebo or excipients 10. Congestive heart failure 11. Significant cardiovascular history 12. History of haemoglobinopathies 13. History of alcohol abuse or illegal drug abuse within the past 12 months 14. Involvement in the planning and conduct of the study 15. Previous enrolment or randomization of treatment in the present study 16. Participation in a clinical study during the last 90 days prior to visit 1 17. Donation of blood, plasma or platelets within the past 3 months prior to visit 1 18. Individuals who could render the patient unable to complete the study 19. Suspected or confimed poor protocol or medication compliance
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To compare that after 52-week oral administration of double-blind treatment, the absolute change from baseline in glycosylated haemoglobin A1c (HBA1c) level with saxagliptin plus metformin is non-inferior to glipizide (sulphonylurea) plus metformin in patients with type 2 diabetes who have inadequate glycaemic control on 1500 mg or higher doses of metformin alone.;Secondary Objective: Three secondary objectives among all secondary objectives, are identified a priori for special attention to compare the effects of saxagliptin versus glipizide given as add-on therapy to metformin after a 52-week double-blind treatment period by evaluation of: - Proportion of patients reporting at least one episode of hypoglycaemic event at week 52. - Change from baseline in body weight at week 52. - Durability of HbA1c effect based on week 24 over the 52 weeks as an efficacy objective;Primary end point(s): The primary outcome variable is the change from baseline in HbA1c at 52 weeks of treatment | — |
Countries
Finland, Germany, Hungary, Netherlands, United Kingdom
Outcome results
None listed